Original Article

The efectiveness of narrowband ultraviolet B (NB-UVB) in Vitiligo Management and its Association with Thyroid Stimulating Hormone (TSH) level in Indonesian population

Farida Tabri

Farida Tabri
Department of Dermatology and Venereology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. Email: farida.tabri.dv@gmail.com
Online First: December 01, 2018 | Cite this Article
Tabri, F. 2018. The efectiveness of narrowband ultraviolet B (NB-UVB) in Vitiligo Management and its Association with Thyroid Stimulating Hormone (TSH) level in Indonesian population. Journal of Dentomaxillofacial Science 3(3): 149-151. DOI:10.15562/jdmfs.v3i3.843


Objective: Vitiligo is an autoimmune disease marked by the presence of hypopigmented macules due to the reduction in the number and function of melanocytes. Besides its adverse cosmetic effect, vitiligo is also associated with other autoimmune diseases such as thyroid disorders. Ultraviolet irradiation, especially narrowband ultraviolet B (NB-UVB), has been widely used in treating vitiligo despite the unclear mechanism. However, such studies in Indonesian population are very limited. This study aims to examine the efficacy of NB-UVB in vitiligo treatment and its effect of thyroid function in Indonesian population.

Material and Methods: Twenty-two vitiligo patients aged 4-54 years old were treated three times weekly with NB-UVB. The minimal erythema dose (MED) was determined and an initial dose of 50% MED dose was commenced three times per week. The dose was increased gradually while assessing for the treatment response. The change in depigmentation rate, vitiligo area severity index (VASI), and the level of thyroid stimulating hormone (TSH) were assessed before and after therapy using Wilcoxon test.

Results: Depigmentation rate and VASI score were found to decrease after treatment, although the change was not statistically siginificant. Two patients showed an decrease in depigmentation rate of more than 75%. The TSH level significantly decreased after treatment (p>0.05). The most common side effect found was the combination between erythema, soreness, and pruritus.

Conclusion: Our study shows that NB-UVB therapy results in improved depigmentation, VASI score and a reduced TSH level in vitiligo patients.

References

Manga P, Elbuluk N, Orlow SJ. Recent advances in understanding vitiligo. F1000 Res 2016;5: 2234.

Amerio P, Tracanna M, De-Remigis P, et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+ C and 4. CPD 2006;31: 746-749.

Rodrigues M, Ezzedine K, Hamzavi I, et al. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 2017;77: 1-13.

Vrijman C, Kroon M, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol 2012;167: 1224-1235.

Lu T, Gao T, Wang A, et al. Vitiligo prevalence study in Shaanxi Province, China. Int J Dermatol 2007;46: 47-51.

Patil S, Gautam M, Nadkarni N, et al. Gender differences in clinicoepidemiological features of vitiligo: a cross-sectional analysis. ISRN Dermatol 2014;2014: 186-197.

Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: a meta-analysis. PLoS One 2016;11: e0163806-e.

Dillon AB, Sideris A, Hadi A, et al. Advances in vitiligo: an update on medical and surgical treatments. JCAD 2017;10: 15-28.

Bansal S, Sahoo B, Garg V. Psoralen-narrowband UVB phototherapy for the treatment of vitiligo in comparison to narrowband UVB alone. Photodermatol Photoimmunol Photomed 2013;29: 311-317.

Yones SS, Palmer RA, Garibaldinos TM, et al. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy. Arch Dermatol 2007;143: 578-584.

Gupta Y, Ammini AC. Vitiligo, hypothyroidism and cardiomyopathy. Indian J Endocrinol Metab 2012;16: 463-465.

Baldini E, Odorisio T, Sorrenti S, et al. Vitiligo and autoimmune thyroid disorders. Front Endocrinol (Lausanne) 2017;8: 290.

Jin Y, Birlea SA, Fain PR, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 2012;44: 676.

Czajkowski R, Męcińska-Jundziłł K. Current aspects of vitiligo genetics. Adv Dermatol & Allergol/Postȩpy Dermatol Alergol 2014;31: 247.

Kumar YHK, Rao GRR, Gopal K, et al. Evaluation of narrow-band UVB phototherapy in 150 patients with vitiligo. Indian J Dermatol, Venereol, Leprol 2009;75: 162.


No Supplementary Material available for this article.
Article Views      : 17
PDF Downloads : 8

Related Articles

Search Authors in












  • Farida Tabri

  • Farida Tabri

  • Farida Tabri